2023
Imaging biomarkers in aortic valve disease: it is time to shift the focus to the myocardium
Kwon D, Akintoye E. Imaging biomarkers in aortic valve disease: it is time to shift the focus to the myocardium. European Heart Journal - Cardiovascular Imaging 2023, 24: 863-865. PMID: 37220177, DOI: 10.1093/ehjci/jead095.Peer-Reviewed Original Research
2021
Prognostic Implications of Ambulatory N-Terminal Pro-B-Type Natriuretic Peptide Changes in Patients with Continuous-Flow Left Ventricular Assist Devices
Ali A, Akintoye E, Duque E, Kshetri R, Shetty S, Sharma U, Johnson C, Panos A, Briasoulis A, Alvarez P. Prognostic Implications of Ambulatory N-Terminal Pro-B-Type Natriuretic Peptide Changes in Patients with Continuous-Flow Left Ventricular Assist Devices. ASAIO Journal 2021, 68: 524-530. PMID: 34352812, DOI: 10.1097/mat.0000000000001524.Peer-Reviewed Original ResearchConceptsNT-pro BNP concentrationHF hospitalizationBNP concentrationsVentricular assist devicePrognostic implicationsN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideAssist deviceHeart failure hospitalizationNT-pro BNPFailure hospitalizationIndex hospitalizationAdverse eventsLVAD implantationConsecutive patientsAmbulatory patientsNatriuretic peptideRetrospective studyHospitalizationAmbulatory settingPatientsMonth baselineMonthsDeathUnit increasePrognostic Utility of Risk Enhancers and Coronary Artery Calcium Score Recommended in the 2018 ACC/AHA Multisociety Cholesterol Treatment Guidelines Over the Pooled Cohort Equation: Insights From 3 Large Prospective Cohorts
Akintoye E, Afonso L, Jayanna M, Bao W, Briasoulis A, Robinson J. Prognostic Utility of Risk Enhancers and Coronary Artery Calcium Score Recommended in the 2018 ACC/AHA Multisociety Cholesterol Treatment Guidelines Over the Pooled Cohort Equation: Insights From 3 Large Prospective Cohorts. Journal Of The American Heart Association 2021, 10: e019589. PMID: 34092110, PMCID: PMC8477885, DOI: 10.1161/jaha.120.019589.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmerican Heart AssociationBiomarkersCardiovascular DiseasesCholesterolClinical Decision-MakingCoronary Artery DiseaseDecision Support TechniquesDyslipidemiasFemaleHeart Disease Risk FactorsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIncidenceMaleMiddle AgedPractice Guidelines as TopicPredictive Value of TestsPrimary PreventionPrognosisRisk AssessmentTime FactorsUnited StatesVascular CalcificationConceptsPooled Cohort EquationsCoronary artery calcium scoreCholesterol treatment guidelinesArtery calcium scoreAtherosclerotic cardiovascular diseaseCohort EquationsRisk enhancersCalcium scoreTreatment guidelinesCardiovascular diseaseAmerican Heart Association/American CollegeAtherosclerotic cardiovascular disease eventsBackground Limited dataIntermediate-risk participantsIntermediate-risk patientsCardiovascular disease eventsLarge prospective cohortIncremental valueNet reclassification indexStatin therapyCAC testingProspective cohortPrognostic utilityC-statisticReclassification index
2019
A Doppler Echocardiographic Pulmonary Flow Marker of Massive or Submassive Acute Pulmonary Embolus
Afonso L, Sood A, Akintoye E, Gorcsan J, Rehman M, Kumar K, Javed A, Kottam A, Cardozo S, Singh M, Palla M, Ando T, Adegbala O, Shokr M, Briasoulis A. A Doppler Echocardiographic Pulmonary Flow Marker of Massive or Submassive Acute Pulmonary Embolus. Journal Of The American Society Of Echocardiography 2019, 32: 799-806. PMID: 31056367, DOI: 10.1016/j.echo.2019.03.004.Peer-Reviewed Original ResearchConceptsMassive pulmonary embolismSubmassive pulmonary embolismPulmonary embolismSubsegmental pulmonary embolismMcConnell's signExtent of PEDoppler flow patternsAcute pulmonary emboliFuture prospective studiesCharacteristic curve analysisSpectral Doppler interrogationAlternative imaging modalityNoninvasive signsUnderwent echocardiographyEchocardiographic parametersPulmonary hypertensionPulmonary emboliEchocardiography parametersProspective studyDoppler interrogationTomographic angiographyDeceleration timeDoppler variablesClinical utilityPatients
2017
Biochemical risk markers and 10-year incidence of atherosclerotic cardiovascular disease: independent predictors, improvement in pooled cohort equation, and risk reclassification
Akintoye E, Briasoulis A, Afonso L. Biochemical risk markers and 10-year incidence of atherosclerotic cardiovascular disease: independent predictors, improvement in pooled cohort equation, and risk reclassification. American Heart Journal 2017, 193: 95-103. PMID: 29129262, DOI: 10.1016/j.ahj.2017.08.002.Peer-Reviewed Original ResearchConceptsPooled Cohort EquationsNet reclassification indexBiochemical risk markersBiomarker scoreCohort EquationsC-statisticRisk markersTreatment decisionsPrimary atherosclerotic cardiovascular disease (ASCVD) preventionAtherosclerotic cardiovascular disease preventionCategorical net reclassification indexSensitivity C-reactive proteinCategory-free net reclassification indexN-terminal prohormoneBrain natriuretic peptideAtherosclerotic cardiovascular diseaseCardiovascular disease preventionC-reactive proteinMulti-Ethnic StudyRate of incidentsASCVD preventionIndependent predictorsNet reclassificationNatriuretic peptideRisk reclassification
2016
Novel biomarkers with potential for cardiovascular risk reclassification
Mallikethi-Reddy S, Briasoulis A, Akintoye E, Afonso L. Novel biomarkers with potential for cardiovascular risk reclassification. Biomarkers 2016, 22: 189-199. PMID: 27299923, DOI: 10.1080/1354750x.2016.1201540.Peer-Reviewed Original ResearchConceptsRed cell distribution widthCardiovascular risk reclassificationRisk reclassificationNovel risk markersCardiovascular risk predictionCell distribution widthCardiovascular riskCVD eventsMultivariate risk modelIntermediate riskAbsolute riskAsymptomatic individualsSerum biomarkersRisk markersTreatment recommendationsRisk factorsCystatin CNovel biomarkersRisk modelDistribution widthBiomarkersRisk predictionPatientsRiskReclassification